...
机译:兔胸腺嘧啶的兔胸腺嘧啶在不明,寄和杂草,造血干细胞移植调理方案中的最佳剂量:前瞻性随机试验的长期结果
Peking Univ Inst Hematol Peoples Hosp 11 Xizhimen South St Beijing 100044 Peoples R China;
Peking Univ Inst Hematol Peoples Hosp 11 Xizhimen South St Beijing 100044 Peoples R China;
Peking Univ Inst Hematol Peoples Hosp 11 Xizhimen South St Beijing 100044 Peoples R China;
Peking Univ Inst Hematol Peoples Hosp 11 Xizhimen South St Beijing 100044 Peoples R China;
Peking Univ Inst Hematol Peoples Hosp 11 Xizhimen South St Beijing 100044 Peoples R China;
Peking Univ Inst Hematol Peoples Hosp 11 Xizhimen South St Beijing 100044 Peoples R China;
Peking Univ Inst Hematol Peoples Hosp 11 Xizhimen South St Beijing 100044 Peoples R China;
Peking Univ Inst Hematol Peoples Hosp 11 Xizhimen South St Beijing 100044 Peoples R China;
Peking Univ Inst Hematol Peoples Hosp 11 Xizhimen South St Beijing 100044 Peoples R China;
Peking Univ Inst Hematol Peoples Hosp 11 Xizhimen South St Beijing 100044 Peoples R China;
Peking Univ Inst Hematol Peoples Hosp 11 Xizhimen South St Beijing 100044 Peoples R China;
Peking Univ Inst Hematol Peoples Hosp 11 Xizhimen South St Beijing 100044 Peoples R China;
Peking Univ Inst Hematol Peoples Hosp 11 Xizhimen South St Beijing 100044 Peoples R China;
Peking Univ Inst Hematol Peoples Hosp 11 Xizhimen South St Beijing 100044 Peoples R China;
antithymocyte globulin; chronic graft-versus-host disease (cGVHD); graft-versus-host disease-free/recurrence-free survival; haploidentical; hematopoietic stem cell transplantation; late effects;
机译:兔胸腺嘧啶的兔胸腺嘧啶在不明,寄和杂草,造血干细胞移植调理方案中的最佳剂量:前瞻性随机试验的长期结果
机译:基于血液恶性肿瘤的FBCA调理方案的HLA单倍型造血干细胞移植的长期结果而无体外T细胞耗竭
机译:使用氟氮胺胺,减少剂量环磷酰胺和低剂量胸腺素具有预移植预处理的异种造血干细胞移植及低剂量胸腺素:KSGCT前瞻性研究
机译:高剂量梅酚和自体干细胞移植串联循环治疗Al淀粉样态的治疗方法:最终分析对前瞻性试验
机译:免疫抑制剂用于造血干细胞移植的调理方案
机译:单剂大剂量美法仑在霍奇金淋巴瘤自体造血干细胞移植中作为调理方案:安全性和长期疗效。
机译:错误:Chang Y-J,Wang Y,Mo X-D等人。兔胸腺嘧啶含量兔胸腺嘧啶,造血干细胞移植调节方案:预期随机试验的长期结果。癌症。 2017; 123:28